We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+8.89%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.02B
AUM Growth
+$60.4M
Cap. Flow
-$61.1M
Cap. Flow %
-5.98%
Top 10 Hldgs %
49.68%
Holding
183
New
37
Increased
35
Reduced
45
Closed
53

Top Buys

Rank Stock Value
1
BCOM
B Communications Ltd
BCOM
+$95.7M
2
BIIB icon
Biogen
BIIB
+$20.4M
3
CELG
Celgene Corp
CELG
+$10.3M
4
CXRX
Concordia International Corp. Common Stock
CXRX
+$7.22M
5
ATXS
Astria Therapeutics
ATXS
+$5.62M

Top Sells

Rank Stock Value
1
ENDP
Endo International plc
ENDP
+$18.8M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$13.9M
3
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$12.5M
4
AMGN icon
Amgen
AMGN
+$9.61M
5
IWM icon
iShares Russell 2000 ETF
IWM
+$6.98M

Sector Composition

Rank Sector Weight
1 Healthcare 50.75%
2 Technology 3.95%
3 Utilities 1.35%
4 Industrials 0.96%
5 Consumer Discretionary 0.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PVLA
76
Palvella Therapeutics
PVLA
$1.99B
$3.3M 0.32%
+15,000
New +$3.3M
RPTP
77
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$3.26M 0.32%
+206,500
New +$2.51M
TXMD icon
78
TherapeuticsMD
TXMD
$23.5M
$3.24M 0.32%
8,250
+950
+13% +$335K
MGNX icon
79
MacroGenics
MGNX
$235M
$3.23M 0.32%
85,000
+25,000
+42% +$822K
TRIL
80
DELISTED
Trillium Therapeutics Inc.
TRIL
$3.21M 0.31%
147,000
+52,000
+55% +$1.19M
PTCT icon
81
PTC Therapeutics
PTCT
$5.68B
$3.2M 0.31%
66,500
-3,500
-5% -$204K
XLRN
82
DELISTED
Acceleron Pharma
XLRN
$3.16M 0.31%
+100,000
New +$3.23M
PAY
83
DELISTED
Verifone Systems Inc
PAY
$3.16M 0.31%
93,055
+17,510
+23% +$635K
QURE icon
84
uniQure
QURE
$3.03B
$3.1M 0.3%
115,000
+12,585
+12% +$358K
FPRX
85
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$3.1M 0.3%
+125,000
New +$2.78M
AGTC
86
DELISTED
Applied Genetic Technologies Corporation
AGTC
$3.07M 0.3%
200,124
-35,000
-15% -$671K
MLNX
87
DELISTED
Mellanox Technologies, Ltd.
MLNX
$3.05M 0.3%
+62,850
New +$3.05M
ABUS icon
88
Arbutus Biopharma
ABUS
$857M
$3.02M 0.3%
255,000
-43,486
-15% -$662K
MRTX
89
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$2.99M 0.29%
95,000
-5,000
-5% -$147K
AAPL icon
90
Apple
AAPL
$4.54T
$2.91M 0.29%
92,892
-78,040
-46% -$2.5M
IMDZ
91
DELISTED
Immune Design Corp.
IMDZ
$2.89M 0.28%
140,000
+10,560
+8% +$249K
PTCT icon
92
CALL
PTC Therapeutics
PTCT
$5.68B
$2.89M 0.28%
600
– –
SBUX icon
93
Starbucks
SBUX
$120B
$2.87M 0.28%
53,583
-121,033
-69% -$6.14M
MDCO
94
CALL
DELISTED
Medicines Co
MDCO
$2.86M 0.28%
1,000
– –
KALV
95
DELISTED
KalVista Pharmaceuticals
KALV
$2.86M 0.28%
+28,571
New +$2.83M
WIX icon
96
WIX.com
WIX
$2.3B
$2.84M 0.28%
+120,305
New +$2.74M
CYTK icon
97
Cytokinetics
CYTK
$10.5B
$2.84M 0.28%
+422,250
New +$2.77M
CLCD
98
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$2.82M 0.28%
+317,250
New +$2.72M
IONS icon
99
Ionis Pharmaceuticals
IONS
$8.6B
$2.76M 0.27%
+48,000
New +$3.05M
SCYX icon
100
SCYNEXIS
SCYX
$48.1M
$2.75M 0.27%
+3,913
New +$2.81M
2 3
4
5 6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2015 Portfolio in Review

As of Q2 2015, Sphera Funds Management held 183 positions worth $1.02B, up 6.3% from $961M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Sphera Funds Management withdrew a net $61.1M in Q2 2015, closing 53 positions and reducing 45 holdings. Its most notable exit was Endo International plc, an estimated $18.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, down from 54% a quarter earlier, followed by Technology and Utilities.

Against the trend, Sphera Funds Management opened a new position in B Communications Ltd worth $6.45M.

  • Sphera Funds Management's largest Q2 2015 buy was B Communications Ltd: 5,977,000 shares worth $6.45M.
  • Sphera Funds Management added most to Biogen in Q2 2015, an estimated $20.4M increase.
  • Sphera Funds Management's biggest Q2 2015 reduction was Teva Pharmaceuticals, cutting an estimated $13.9M.
  • Sphera Funds Management fully exited Endo International plc in Q2 2015, selling an estimated $18.8M.
  • Sphera Funds Management's ten largest holdings make up 50% of its $1.02B portfolio in Q2 2015.
  • Sphera Funds Management opened 37 new positions and closed 53 in Q2 2015.
  • Sphera Funds Management's portfolio value rose 6.3% quarter-over-quarter to $1.02B.

Based on Sphera Funds Management's 13F filing for Q2 2015, filed 6 Aug 2015.